Skip to main content
AVCRF
OTC Life Sciences

Avricore Health Closes Upsized $1.254M Private Placement with Insider Participation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.056
Mkt Cap
$5.672M
52W Low
$0.015
52W High
$0.079
52W Position info
271% above low
Off High info
29% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AVCRF has more than doubled off its 52-week low of $0.015.

Summary

Avricore Health closed a $1.254 million private placement at $0.05 per unit, upsized from the original $1.25 million, with insider participation of $200,000. The funds are earmarked for UK expansion amid a going-concern warning and severe revenue decline.


Key Events · Financing and Capital Events · AVCRF

  • Private Placement Closed

    The company closed a non-brokered private placement on June 16, 2026, issuing 25,080,000 units at $0.05 per unit for gross proceeds of $1,254,000, upsized from the originally announced $1,250,000.

  • Insider Participation

    Insiders, including certain directors and officers, purchased 4,000,000 units for $200,000, a related-party transaction exempt from formal valuation and minority approval requirements.

  • Finder's Fee

    Canaccord Genuity Corp. received a cash commission of $54,600 and 1,092,000 non-transferable finder's warrants exercisable at $0.05 for two years.

  • Use of Proceeds

    Proceeds will be used for general working capital, supporting the company's UK expansion strategy amid a going-concern warning and 89% revenue decline.


Analysis · AVCRF · Life Sciences

Avricore Health closed its previously announced private placement, raising $1.254 million—slightly above the $1.25 million target. The financing is critical for the company's UK expansion, especially given its going-concern warning and 89% revenue decline. Insiders put in $200,000, signaling commitment, but the deal is highly dilutive at $0.05 per unit with half-warrants exercisable at $0.10, potentially doubling the share count if exercised. The company's market cap is only about $5.7 million, so this raise is significant for extending its cash runway.

At the time of this filing, AVCRF was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.02 to $0.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVCRF - Latest Insights

AVCRF
Jul 10, 2026, 8:19 PM EDT
Filing Type: 6-K
Importance Score:
8
AVCRF
Jun 11, 2026, 6:12 AM EDT
Filing Type: 6-K
Importance Score:
8
AVCRF
May 08, 2026, 7:01 PM EDT
Filing Type: 6-K
Importance Score:
9
AVCRF
Feb 17, 2026, 6:15 AM EST
Filing Type: 6-K
Importance Score:
8
AVCRF
Jan 12, 2026, 3:09 PM EST
Filing Type: 6-K
Importance Score:
9